程序性细胞死亡配体1（PD-L1），也称为B7-H1或CD274，是一种B7家族蛋白，参与调节和减弱适应性免疫应答和外周T细胞耐受性。1、2、3、4它是一种290个氨基酸的I型跨膜蛋白，在人类中由CD274编码，一个IgV样结构域，一个IgC样结构域、一个跨膜结构域和一个细胞质尾部。PD-L1在T和B细胞、树突状细胞、巨噬细胞和调节性T细胞（Tregs）以及多种非造血细胞中组成性表达，并被IFN-γ上调，抑制T细胞增殖、迁移和细胞因子产生。PD-L1也在多种肿瘤细胞中异常表达，肿瘤组织中PD-L1的表达与肾细胞癌患者的不良预后相关。含有PD-L1阻断抗体的制剂已用于治疗多种癌症。Cayman的PD-L1/CD274兔单克隆抗体（APC）由与别藻蓝蛋白（APC）缀合的PD-L1/CD274单克隆抗体组成，可用于流式细胞术。

Cayman Chemical艾美捷PD-L1/CD274兔单克隆抗体技术参数：

免疫原：重组小鼠PD-L1

配方：蛋白A亲和纯化单克隆抗体

宿主：兔子

同种型：IgG抗体

应用：FC、Cross Reactivity、(+) PD-L1

存储：4摄氏度

稳定性：≥1年

Cayman Chemical艾美捷PD-L1/CD274兔单克隆抗体相关文献：

1. Fabrizio, F.P., Trombetta, D., Rossi, A., et al. Gene code CD274/PD-L1: From molecular basis toward cancer immunotherapy. Ther. Adv. Med. Oncol. 10, (2018).

2. Riley, J.L. PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114-125 (2009).

3. del Rio, M.L., Buhler, L., Gibbons, C.E., et al. PD-1/PD-L1, PD-1/PD-L2, ａnd other co-inhibitory signaling pathways in transplantation. Transpl. Int. 21(11), 1015-1028 (2008).

4. Akinleye, A., ａnd Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12(1), 92 (2019).

5. Keir, M.E., Butte, M.J., Freeman, G.J., et al. PD-1 ａnd its ligands in tolerance ａnd immunity. Annu. Rev. Immunol. 26, 677-704 (2008).

6. Ji, M., Liu, Y., Li, Q., et al. PD-1/PD-L1 pathway in non-small-cell lung cancer ａnd its relation with EGFR mutation. J. Transl. Med. 13, 5 (2015).

7. Thompson, R.H., Dong, H., Lohse, C.M., et al. PD-1 is expressed by tumor-infiltrating immune cells ａnd is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13(6), 1757-1761 (2007).

8. Thompson, R.H., Kuntz, S.M., Leibovich, B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).

Cayman Chemical涉及癌症、肿瘤、氧化损伤、凋亡、氧化性损伤、代谢、内分泌学等多种研究域。艾美捷科技是Cayman Chemical的中国代理商，为科研工作者提供优质的产品与服务。

来源：https://www.amyjet.com/brand/cayman-china-distributor.shtml